- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01667978
The Effect of Protease Inhibitors on the Pharmacokinetics of Oral Norethindrone Contraception (NET)
Study Overview
Detailed Description
BACKGROUND/RATIONALE : It is recognized that there is a dearth of clinically applied, population based, empiric data to guide contraceptive recommendations in HIV + women on ARVs.(1) Protease inhibitors (PI) and non nucleoside reverse transcriptase inhibitors (NNRTI ) induce micro enzyme systems such as CYP 3a4, which in turn alters the bio-availability and pharmacokinetics of other concurrently administered medications.(2) Empiric trials from small samples, often of 10-20 HIV negative subjects, have demonstrated that concurrent administration of combined oral contraceptives (COC) and a PI or a NNRTI have been associated with decreased plasma ethinyl estradiol (EE) levels. These pharmacokinetic findings have raised concern that decreased bio-availability of EE may result in decreased contraceptive efficacy, with possible increased unintended pregnancy. Some of these COC studies have demonstrated that there is no change in the serum levels of norethindrone (NET) on ARVs.(3-16) However, there are no published trials focused on oral NET or oral progestin-only pills (POP) to guide management in HIV+ women.(17)
OBJECTIVES:
Primary objective of this study is:
To detect a ±40% difference in AUC of serum NET in HIV+ women taking ATV/RTV as compared to AUC of NET in HIV+ women taking an ARV regimen that has demonstrated no interaction with NET in the past.
Primary endpoint: Natural log-transformed NET PK parameter AUC from 0 to 72 hours following oral administration, with multiple discrete serum data points for each subject on ATV/RTV. This will be compared to natural log-transformed NET PK AUC from 0 to 72 hours following oral administration, with multiple discrete serum data points for controls HIV+ women taking an ARV regimen that has demonstrated no interaction with NET in the past.
The secondary objectives of this study are:
To evaluate the effect of ATV/RTV on other PK exposure endpoints and parameters of NET (with natural log transformation). The sample and control groups mentioned above will again be compared. Endpoints include:
minimum plasma concentration (Cmin), maximum plasma concentration (Cmax), time to Cmax (Tmax), and half-life (T1/2).
SAMPLE SIZE: Recruitment of 16 participants in each arm, with the goal of attaining 32 evaluable HIV-1-seropositive female subjects in total.
POPULATION/STUDY ARMS: HIV-1-infected female subjects 18-44 years of age
METHODOLOGY/INTERVENTIONS/FOLLOW-UP: A two-arm, open-label, prospective, steady state trial to characterize the pharmacokinetics (PK) of oral norethindrone (NET) as a progestin only contraceptive pill (POP) in HIV+ women receiving atazanavir and ritonavir therapy (ATV/RTV). The investigators will identify a control group of HIV+ women who are taking ARV regimens that have not significantly altered oral NET levels in prior trials. Subjects will be enrolled in the trial for approximately 4 weeks A 28 day continuous packet of NET 0.35 mg will be provided to all enrolled volunteers for 21 days of continuous administration. Women who participate in this study will demonstrate a means of continuing their ARV regimens for the duration of the study, ARV therapy will not be provided by this study. On day 22 subjects will be admitted for serial pharmacokinetic (PK) specimens collection following the final study dose of NET.
Subjects will be enrolled into one of the 2 arms based on their current ARV regimen.
Study group: Women on stable ARV/RTV (300/100mg daily) with additional ARV regimens that have not significantly altered oral NET levels in prior trials. (n=12).
Control group: Stable on current ARV, no protease inhibitors (PI), ARV regimens that have not significantly altered oral NET levels in previous research.
OUTCOMES: Intensive PK sampling for NET will be performed in those in intervention and control arms after 21 days of NET administration. To determine side effect profile of NET by self-administered daily questionnaire during the 3-4 week study enrollment period
STATISTICS: Area under the concentration-time curve (AUC), peak plasma concentration, and the lowest plasma concentration for NET in HIV+ women receiving this PI therapy will be determined and compared to similar values in HIV positive control subjects who are not taking PI therapy. Statistical consultation will be obtained from the USC Keck School of Medicine Department of Bio statistics and Laboratory of Applied Pharmacokinetics
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
Los Angeles, California, United States, 90033-1029
- Los Angeles County Hospital University of Southern California (LAC USC)
-
Los Angeles, California, United States, 90033-1029
- Los Angeles County University of Southern California
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Ages: 18-44 years Gender: female Accepts: healthy volunteers and HIV-1 infected women Acceptable medications include: no other medications, NRTI combinations, entry inhibitors, integrase inhibitors, and CCR5 agonists. NRTI combinations may include but are not limited to: zidovudine (ZDV), lamivudine (3TC), emtricitabine (FTC), didanosine (ddl), stavudine (d4T), abacavir (ABC), and tenofovir disoproxil fumarate (TDF). NNRTI: etravirine, and rilpivirine.
Exclusion criteria:
History of bilateral oophorectomy, ovarian dysfunction or no regular periods. CD4+ cell count <200 cells/mm3 No current or uncontrolled thyroid, liver, or renal disease BMI <40 kg/m^2 Current pregnancy, breastfeeding or pregnancy within 30 days of enrollment. Depomedroxyprogesterone acetate injection (DMPA) within 180 days prior to study entry.
Other hormonal therapies (e.g. oral contraceptive agents, Provera, vaginal ring, contraceptive patch, monthly contraceptive injection, hormone replacement therapy, anabolic therapies, including nandrolone decanoate or megestrol acetate) within the 21 days prior to study entry.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: PI
Study group with PI: atazanavir ritonavir
|
Other Names:
|
Placebo Comparator: Control
o PI therapy, control group
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
AUC Norethindrone
Time Frame: following 21 days of continuous ingestion
|
0, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96 hours post-dose on Day 21
|
following 21 days of continuous ingestion
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Jessica M Atrio, MD, University of Southern California
Publications and helpful links
General Publications
- Atrio J, Stek A, Vora H, Sanchez-Keeland L, Zannat F, Natavio M. The effect of protease inhibitors on the cervical mucus of HIV-positive women taking norethindrone contraception. Eur J Contracept Reprod Health Care. 2015 Apr;20(2):149-53. doi: 10.3109/13625187.2014.957826. Epub 2014 Oct 6.
- DuBois BN, Atrio J, Stanczyk FZ, Cherala G. Increased exposure of norethindrone in HIV+ women treated with ritonavir-boosted atazanavir therapy. Contraception. 2015 Jan;91(1):71-5. doi: 10.1016/j.contraception.2014.08.009. Epub 2014 Aug 30.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 Enzyme Inhibitors
- Contraceptive Agents, Hormonal
- Contraceptive Agents
- Reproductive Control Agents
- Contraceptives, Oral
- Contraceptive Agents, Female
- Contraceptives, Oral, Synthetic
- HIV Protease Inhibitors
- Viral Protease Inhibitors
- Contraceptives, Oral, Hormonal
- Ritonavir
- Protease Inhibitors
- Atazanavir Sulfate
- Norethindrone
- Norethindrone Acetate
Other Study ID Numbers
- HS-12-00005
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pregnancy
-
Far Eastern Memorial HospitalCompletedCornual PregnancyTaiwan
-
Peking Union Medical College HospitalPeking Union Medical CollegeUnknownPregnancy | Pregnancy Related | Infant | Pregnancy Disease | Risk FactorChina
-
Ufuk UniversityNot yet recruitingPregnancy Complications | Pregnancy Loss | Pregnancy Preterm
-
Hadassah Medical OrganizationCompleted
-
Centre Hospitalier Universitaire de Saint EtienneCompletedProlonged PregnancyFrance
-
University Hospital, ToursCompleted
-
Technische Universität DresdenWithdrawnPregnancy Trimester, Second | Pregnancy Trimester, First | Pregnancy Trimester, ThirdGermany
-
Turku University HospitalUniversity of TurkuCompleted
-
Universitair Ziekenhuis BrusselMerck Serono International SAUnknownPregnancy | Pregnancy LossBelgium
-
Hopital Antoine BeclereUnknown
Clinical Trials on Norethindrone acetate
-
Milton S. Hershey Medical CenterCompleted
-
Boston Children's HospitalBrigham and Women's HospitalCompleted
-
Baylor Research InstituteMerck Sharp & Dohme LLCTerminatedContraception | Breakthrough Bleeding | Implant | Birth Control | Uterine BleedingUnited States
-
Scott and White Hospital & ClinicUnknownMenorrhagia | Heavy Menstrual Bleeding | HypermenorrheaUnited States
-
Norton HealthcareCompletedEtonogestrel Contraceptive Implant, Bothersome BleedingUnited States
-
Teva Pharmaceuticals USACompleted
-
Teva Pharmaceuticals USACompleted
-
Boston Children's HospitalNot yet recruiting
-
Assiut UniversityNot yet recruiting